1. 調査手法および範囲
1.1. 調査手法
1.2. 調査目的およびレポートの範囲
2. 定義および概要
3. エグゼクティブサマリー
3.1. 種類別抜粋
3.2. 技術別抜粋
3.3. 用途別抜粋
3.4. エンドユーザー別抜粋
3.5. 地域別抜粋
4. ダイナミクス
4.1. 影響要因
4.1.1. 推進要因
4.1.1.1. 慢性疾患の増加
4.1.2. 抑制要因
4.1.2.1. 規制上の課題
4.1.3. 機会
4.1.4. 影響分析
5. 産業分析
5.1. ポーターのファイブフォース分析
5.2. サプライチェーン分析
5.3. 価格分析
5.4. 規制分析
5.5. 償還分析
5.6. 特許分析
5.7. SWOT分析
5.8. DMIの意見
6. 臓器の種類別
6.1. はじめに
6.1.1. 市場規模分析および前年比成長率分析（％）、種類別
6.1.2. 市場魅力度指数、種類別
6.2. 心臓*
6.2.1. はじめに
6.2.2. 市場規模分析および前年比成長率分析（％）
6.3. 肝臓
6.4. 腎臓
6.5. 肺
6.6. 皮膚
6.7. 骨
7. 技術別
7.1. はじめに
7.1.1. 市場規模分析および前年比成長率分析（％）、技術別
7.1.2. 市場魅力度指数、技術別
7.2. 押出ベースの3Dプリンティング*
7.2.1. はじめに
7.2.2. 市場規模分析および前年比成長率分析（％）
7.3. レーザー支援印刷
7.4. インクジェット印刷
7.5. 磁気浮上
8. 用途別
8.1. はじめに
8.1.1. 市場規模分析および前年比成長率分析（％）、用途別
8.1.2. 用途別市場魅力度指数
8.2. ティッシュエンジニアリング*
8.2.1. はじめに
8.2.2. 市場規模分析および前年比成長率分析（%）
8.3. 再生医療
8.4. 創薬
8.5. 外科的計画
9. エンドユーザー別
9.1. はじめに
9.1.1. エンドユーザー別市場規模分析および前年比成長率（％）
9.1.2. エンドユーザー別市場魅力度指数
9.2. 病院および診療所*
9.2.1. はじめに
9.2.2. エンドユーザー別市場規模分析および前年比成長率（％）
9.3. 研究機関および研究所
9.4. 製薬企業
9.5. 学術機関
10. 地域別
10.1. はじめに
10.1.1. 市場規模分析および前年比成長率分析（％）、地域別
10.1.2. 市場魅力度指数、地域別
10.2. 北米
10.2.1. はじめに
10.2.2. 主要地域別ダイナミクス
10.2.3. 市場規模分析および前年比成長率分析（％）、種類別
10.2.4. 市場規模分析および前年比成長率分析（％）、技術別
10.2.5. 市場規模分析および前年比成長率分析（％）、用途別
10.2.6. エンドユーザー別市場規模分析および前年比成長率分析（％）
10.2.7. 国別市場規模分析および前年比成長率分析（％）
10.2.7.1. 米国
10.2.7.2. カナダ
10.2.7.3. メキシコ
10.3. ヨーロッパ
10.3.1. はじめに
10.3.2. 主要地域別の動向
10.3.3. 市場規模分析および前年比成長率分析（％）、種類別
10.3.4. 市場規模分析および前年比成長率分析（％）、技術別
10.3.5. 市場規模分析および前年比成長率分析（％）、用途別
10.3.6. エンドユーザー別市場規模分析および前年比成長率分析（％）
10.3.7. 国別市場規模分析および前年比成長率分析（％）
10.3.7.1. ドイツ
10.3.7.2. 英国
10.3.7.3. フランス
10.3.7.4. イタリア
10.3.7.5. スペイン
10.3.7.6. ヨーロッパのその他地域
10.4. 南アメリカ
10.4.1. はじめに
10.4.2. 地域特有の主な動向
10.4.3. 市場規模分析および前年比成長率分析（％）、機器の種類別
10.4.4. 市場規模分析および前年比成長率（％）、技術別
10.4.5. 市場規模分析および前年比成長率（％）、用途別
10.4.6. 市場規模分析および前年比成長率（％）、エンドユーザー別
10.4.7. 市場規模分析および前年比成長率（％）、国別
10.4.7.1. ブラジル
10.4.7.2. アルゼンチン
10.4.7.3. 南米その他
10.5. アジア太平洋地域
10.5.1. はじめに
10.5.2. 地域特有の主な動向
10.5.3. 市場規模分析および前年比成長率分析（％）、臓器種類別
10.5.4. 市場規模分析および前年比成長率分析（％）、技術別
10.5.5. 市場規模分析および前年比成長率分析（％）、用途別
10.5.6. 市場規模分析および前年比成長率分析（％）、エンドユーザー別
10.5.7. 市場規模分析および前年比成長率分析（％）、国別
10.5.7.1. 中国
10.5.7.2. インド
10.5.7.3. 日本
10.5.7.4. 韓国
10.5.7.5. アジア太平洋地域その他
10.6. 中東およびアフリカ
10.6.1. はじめに
10.6.2. 主要地域特有の動向
10.6.3. 市場規模分析および前年比成長率分析（％）、種類別
10.6.4. 市場規模分析および前年比成長率分析（％）、種類別
10.6.5. 市場規模分析および前年比成長率分析（％）、用途別
10.6.6. 市場規模分析および前年比成長率分析（％）、エンドユーザー別
11. 競合状況
11.1. 競合シナリオ
11.2. 市場ポジショニング/シェア分析
11.3. 合併・買収分析
12. 企業プロフィール
CELLINK
Organovo Holdings Inc.
CYFUSE BIOMEDICAL K.K.
3D Systems, Inc.
Stratasys
United Therapeutics Corporation
Prellis Biologics
CollPlant Biotechnologies Ltd.
Aspect Biosystems Ltd.
Materialise
リストは網羅的なものではありません
13. 付録
13.1. 当社およびサービスについて
13.2. お問い合わせ
The global 3D printed organ market reached US$ 2.41 billion in 2023 and is expected to reach US$ 6.18 billion by 2031, growing at a CAGR of 12.6% during the forecast period 2024-2031.
A 3D-printed organ is a replica of body tissue created with a 3D bioprinter. They're made out of cellular bio-inks and are artificially grown in a lab. The bioink is designed to help cells build the function and structure of the natural organ it mimics.
Individual patients' distinct anatomical and physiological needs can be addressed using 3D-printed organs. By employing a patient's own cells to construct the organ, the chance of rejection is reduced, resulting in improved outcomes. 3D-printed organs can be used as models to research diseases and test novel medications. This skill enables researchers to gain a better understanding of how diseases affect human tissues and design more effective treatments without having to rely on animal experimentation.
Market Dynamics: Drivers & Restraints
Increasing Prevalence of Chronic Diseases
Chronic disorders such as diabetes, hypertension, and kidney disease are major causes of organ failure. As these disorders become more common around the world, the number of patients seeking organ transplants increases. For instance, there are currently over 103,000 persons on the national transplant waiting list in the United States, with one added every eight minutes, underlining the urgent need for novel approaches like 3D-printed organs to meet this demand.
3D-printed organs can be made from a patient's own cells, increasing biocompatibility and significantly reducing the possibility of transplant rejection. This personalization is especially advantageous for individuals suffering from chronic diseases since it enables individualized treatment options closely aligned with their physiological needs. By addressing compatibility difficulties, 3D-printed organs can boost transplant success rates and patient well-being.
Regulatory Challenges
Regulatory bodies require significant safety and efficacy evidence before approving new medical items. Because 3D-printed organs are custom-made for each patient, typical testing methods such as randomized controlled trials may be ineffective. Each organ is unique, making it difficult to predict outcomes from one example to the next, raising questions about the dependability of safety statistics. The inability to test organs on other people before implantation hampers regulatory evaluations.
Meeting regulatory criteria can be excessively expensive, particularly for bioprinting startups and smaller organizations. Extensive study, testing, and paperwork are required to establish compliance with safety regulations, which may discourage investment and limit innovation. The cost difficulty of navigating regulatory processes may limit the number of market participants.
Segment Analysis
The global 3D printed organ market is segmented based on type, material, fixation type, technology, end-user and region.
Type:
Kidney segment is expected to dominate the 3D-printed organ market share
The kidney segment is likely to dominate the 3D printed organ market due to several compelling factors, including increasing demand for innovative organ transplantation options, rising number of individuals with chronic kidney diseases and others. Kidney transplants account for a substantial share of organ transplant treatments worldwide. For instance, according to the United Network for Organ Sharing, in 2022, 42,887 organ transplants were performed in the United States, an increase of 3.7 percent over 2021.
The significant shortage of suitable donor kidneys is a pressing issue, with over 110,000 people on waiting lists for organ transplants in the United States. Many patients have lengthy waits for a qualified donor, which might last many years. This scarcity emphasizes the urgent requirement for alternative alternatives, such as 3D-printed kidneys, which could be an appealing choice for patients who would otherwise face long wait times or rely on dialysis treatments.
Recent advancements in bioprinting technologies are focused on tackling the complex structures of kidneys, which improves the chances of successfully creating these engineered organs for transplantation. Researchers are consistently improving methods to accurately replicate the intricate functions of kidneys, which is essential for developing organs that can perform the necessary biological tasks effectively.
Geographical Analysis
North America is expected to hold a significant position in the 3D-printed organ market share
North America is at the forefront of the 3D printed organ market, driven by a combination of a strong healthcare system, significant investments in research and development, and an increasing demand for organ transplants. The region has a well-established healthcare infrastructure that supports advanced medical research and innovation, facilitating the integration of cutting-edge technologies like 3D printing into clinical practice. This environment enables rapid advancements in the fabrication of organs.
Moreover, substantial investments from both government and private sectors are directed towards advancing bioprinting technologies in North America. These investments are crucial for developing innovative solutions to address the complexities involved in organ printing, including enhancing bioink formulations and refining printing techniques.
Rising government initiatives to meet the rising demand for organs are also contributing to the overall region’s market growth. For instance, In March 2024, the Advanced Research Projects Agency for Health (ARPA-H), an agency within the U.S. Department of Health and Human Services (HHS), announced the Personalized Regenerative Immunocompetent Nanotechnology Tissue (PRINT) program. The PRINT program aims to create a process to enable biofabrication of the kidney, heart, and liver by leveraging 3D bioprinting, cell manufacturing, biomaterials, modeling, and tissue engineering. The goal is to use patient cells or a biobank to quickly produce immune matched replacement organs and restore normal organ function. These factors are expected to contribute to the region’s market growth.
Asia-Pacific is growing at the fastest pace in the 3D-printed organ market
Asia-Pacific is expected to experience the fastest growth in the global 3D-printed organ market. This is due to rising technological advancement, increasing research and capabilities, and rising funding from the government.
The region faces a significant demand for organ transplants. For instance, according to the publication by Taipei Times in 2022, organ donor registrations dropped by 48 percent during the COVID-19 pandemic, Taiwan Organ Sharing Registry and Patient Autonomy Promotion Center data show. As of the end of June, more than 10,000 people were waiting to receive an organ transplant, including 8,254 people waiting for a kidney, 1,002 people waiting for a liver, 217 people waiting for a heart, 93 people waiting for a lung, and 89 people waiting for a pancreas. Thus, the above factors are rising the region’s growth.
Competitive Landscape
The major global players in the 3D-printed organ market include CELLINK, Organovo Holdings Inc., CYFUSE BIOMEDICAL K.K., 3D Systems, Inc., Stratasys, United Therapeutics Corporation, Prellis Biologics, CollPlant Biotechnologies Ltd., Aspect Biosystems Ltd. and Materialise among others.
Why Purchase the Report?
• Pipeline & Innovations: Reviews ongoing clinical trials, product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
• Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
• Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
• Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
• Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
• Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
• Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
• Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
• Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
• Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
• Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
• Post-market Surveillance: Uses post-market data to enhance product safety and access.
• Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.
The global 3D printed organ market report delivers a detailed analysis with 60+ key tables, more than 50 visually impactful figures, and 176 pages of expert insights, providing a complete view of the market landscape.
Target Audience 2023
• Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
• Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
• Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
• Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
• Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
• Supply Chain: Distribution and Supply Chain Managers.
• Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
• Academic & Research: Academic Institutions.
1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Organ Type
3.2. Snippet by Technology
3.3. Snippet by Application
3.4. Snippet by End-User
3.5. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Increasing Prevalence of Chronic Diseases
4.1.2. Restraints
4.1.2.1. Regulatory Challenges
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Reimbursement Analysis
5.6. Patent Analysis
5.7. SWOT Analysis
5.8. DMI Opinion
6. By Organ Type
6.1. Introduction
6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Organ Type
6.1.2. Market Attractiveness Index, By Organ Type
6.2. Heart*
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Liver
6.4. Kidney
6.5. Lung
6.6. Skin
6.7. Bone
7. By Technology
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
7.1.2. Market Attractiveness Index, By Technology
7.2. Extrusion-Based 3D Printing*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Laser-Assisted Printing
7.4. Inkjet Printing
7.5. Magnetic Levitation
8. By Application
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
8.1.2. Market Attractiveness Index, By Application
8.2. Tissue Engineering*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Regenerative Medicine
8.4. Drug Discovery
8.5. Surgical Planning
9. By End-User
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
9.1.2. Market Attractiveness Index, By End-User
9.2. Hospitals and Clinics*
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Research Institutes and Laboratories
9.4. Pharmaceutical Companies
9.5. Academic Institutions
10. By Region
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
10.1.2. Market Attractiveness Index, By Region
10.2. North America
10.2.1. Introduction
10.2.2. Key Region-Specific Dynamics
10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Organ Type
10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
10.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.2.7.1. The U.S.
10.2.7.2. Canada
10.2.7.3. Mexico
10.3. Europe
10.3.1. Introduction
10.3.2. Key Region-Specific Dynamics
10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Organ Type
10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
10.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.3.7.1. Germany
10.3.7.2. UK
10.3.7.3. France
10.3.7.4. Italy
10.3.7.5. Spain
10.3.7.6. Rest of Europe
10.4. South America
10.4.1. Introduction
10.4.2. Key Region-Specific Dynamics
10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Organ Type
10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
10.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.4.7.1. Brazil
10.4.7.2. Argentina
10.4.7.3. Rest of South America
10.5. Asia-Pacific
10.5.1. Introduction
10.5.2. Key Region-Specific Dynamics
10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Organ Type
10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
10.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.5.7.1. China
10.5.7.2. India
10.5.7.3. Japan
10.5.7.4. South Korea
10.5.7.5. Rest of Asia-Pacific
10.6. Middle East and Africa
10.6.1. Introduction
10.6.2. Key Region-Specific Dynamics
10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Organ Type
10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
10.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
11. Competitive Landscape
11.1. Competitive Scenario
11.2. Market Positioning/Share Analysis
11.3. Mergers and Acquisitions Analysis
12. Company Profiles
12.1. CELLINK*
12.1.1. Company Overview
12.1.2. Product Portfolio and Description
12.1.3. Financial Overview
12.1.4. Key Developments
12.2. SynCOrganovo Holdings Inc.
12.3. CYFUSE BIOMEDICAL K.K.
12.4. 3D Systems, Inc.
12.5. Stratasys
12.6. United Therapeutics Corporation
12.7. Prellis Biologics
12.8. CollPlant Biotechnologies Ltd.
12.9. Aspect Biosystems Ltd.
12.10. Materialise
LIST NOT EXHAUSTIVE
13. Appendix
13.1. About Us and Services
13.2. Contact Us
*** 3Dプリンター製臓器の世界市場に関するよくある質問(FAQ) ***
・3Dプリンター製臓器の世界市場規模は？
→DataM Intelligence社は2023年の3Dプリンター製臓器の世界市場規模を24億1000万米ドルと推定しています。
・3Dプリンター製臓器の世界市場予測は？
→DataM Intelligence社は2031年の3Dプリンター製臓器の世界市場規模を61億8000万米ドルと予測しています。
・3Dプリンター製臓器市場の成長率は？
→DataM Intelligence社は3Dプリンター製臓器の世界市場が2024年～2031年に年平均12.6%成長すると展望しています。
・世界の3Dプリンター製臓器市場における主要プレイヤーは？
→「CELLINK、Organovo Holdings Inc.、CYFUSE BIOMEDICAL K.K.、3D Systems, Inc.、Stratasys、United Therapeutics Corporation、Prellis Biologics、CollPlant Biotechnologies Ltd.、Aspect Biosystems Ltd.、Materialiseなど ...」を3Dプリンター製臓器市場のグローバル主要プレイヤーとして判断しています。
※上記FAQの市場規模、市場予測、成長率、主要企業に関する情報は本レポートの概要を作成した時点での情報であり、最終レポートの情報と少し異なる場合があります。
*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/
